Do analysts rate AMRN or CRDF?

Cardiff Oncology has a consensus price target of $7.50, indicating a potential upside of 472.52%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Cardiff Oncology 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17

Which has stronger valuation & earnings, AMRN or CRDF?

Amarin has higher revenue and earnings than Cardiff Oncology. Amarin is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.41 -$38.80M -$0.65 N/A Cardiff Oncology $590K 151.80 -$45.85M -$0.67 N/A

Does the media prefer AMRN or CRDF?

In the previous week, Amarin had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 4 mentions for Amarin and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.94 beat Amarin's score of 0.43 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CRDF or INDP?

Cardiff Oncology currently has a consensus price target of $7.50, indicating a potential upside of 472.52%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiff Oncology 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to CRDF or INDP?

In the previous week, Indaptus Therapeutics had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 3 mentions for Indaptus Therapeutics and 2 mentions for Cardiff Oncology. Indaptus Therapeutics' average media sentiment score of 1.58 beat Cardiff Oncology's score of 0.94 indicating that Indaptus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indaptus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to FATE or CRDF?

In the previous week, Fate Therapeutics had 5 more articles in the media than Cardiff Oncology. MarketBeat recorded 7 mentions for Fate Therapeutics and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.94 beat Fate Therapeutics' score of 0.67 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRDF or LRMR?

In the previous week, Larimar Therapeutics had 6 more articles in the media than Cardiff Oncology. MarketBeat recorded 8 mentions for Larimar Therapeutics and 2 mentions for Cardiff Oncology. Larimar Therapeutics' average media sentiment score of 1.07 beat Cardiff Oncology's score of 0.94 indicating that Larimar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Larimar Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRDF or IMRX?

In the previous week, Immuneering had 4 more articles in the media than Cardiff Oncology. MarketBeat recorded 6 mentions for Immuneering and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.94 beat Immuneering's score of 0.93 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuneering 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cardiff Oncology (CRDF) Competitors

$1.31 -0.04 (-2.96%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$1.34 +0.03 (+2.21%)

As of 07/14/2026 07:46 PM Eastern

Compare

CRDF vs. AMRN, INDP, FATE, LRMR, and IMRX

Should you buy Cardiff Oncology stock or one of its competitors? MarketBeat compares Cardiff Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardiff Oncology include Amarin (AMRN), Indaptus Therapeutics (INDP), Fate Therapeutics (FATE), Larimar Therapeutics (LRMR), and Immuneering (IMRX). These companies are all part of the "pharmaceutical products" industry.

How does Cardiff Oncology compare to Amarin?

Amarin (NASDAQ:AMRN) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

Amarin has higher revenue and earnings than Cardiff Oncology. Amarin is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.41	-$38.80M	-$0.65	N/A
Cardiff Oncology	$590K	151.80	-$45.85M	-$0.67	N/A

Amarin has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market.

In the previous week, Amarin had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 4 mentions for Amarin and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.94 beat Amarin's score of 0.43 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

22.3% of Amarin shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Amarin has a net margin of -15.51% compared to Cardiff Oncology's net margin of -8,527.43%. Amarin's return on equity of -2.99% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

Cardiff Oncology has a consensus price target of $7.50, indicating a potential upside of 472.52%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

Amarin beats Cardiff Oncology on 10 of the 17 factors compared between the two stocks.

How does Cardiff Oncology compare to Indaptus Therapeutics?

Cardiff Oncology (NASDAQ:CRDF) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Indaptus Therapeutics had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 3 mentions for Indaptus Therapeutics and 2 mentions for Cardiff Oncology. Indaptus Therapeutics' average media sentiment score of 1.58 beat Cardiff Oncology's score of 0.94 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indaptus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Indaptus Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Cardiff Oncology's return on equity of -95.51% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

Cardiff Oncology has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Indaptus Therapeutics has lower revenue, but higher earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	151.80	-$45.85M	-$0.67	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 8.5% of Cardiff Oncology shares are owned by company insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cardiff Oncology currently has a consensus price target of $7.50, indicating a potential upside of 472.52%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cardiff Oncology beats Indaptus Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Cardiff Oncology compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Cardiff Oncology has lower revenue, but higher earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.32M	55.18	-$136.32M	-$1.09	N/A
Cardiff Oncology	$590K	151.80	-$45.85M	-$0.67	N/A

Fate Therapeutics presently has a consensus target price of $5.13, indicating a potential upside of 71.40%. Cardiff Oncology has a consensus target price of $7.50, indicating a potential upside of 472.52%. Given Cardiff Oncology's higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Fate Therapeutics has a beta of 2.51, indicating that its stock price is 151% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market.

97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by insiders. Comparatively, 8.5% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Fate Therapeutics had 5 more articles in the media than Cardiff Oncology. MarketBeat recorded 7 mentions for Fate Therapeutics and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.94 beat Fate Therapeutics' score of 0.67 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fate Therapeutics has a net margin of -2,056.79% compared to Cardiff Oncology's net margin of -8,527.43%. Fate Therapeutics' return on equity of -58.89% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

Summary

Fate Therapeutics beats Cardiff Oncology on 9 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to Larimar Therapeutics?

Cardiff Oncology (NASDAQ:CRDF) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Cardiff Oncology currently has a consensus target price of $7.50, indicating a potential upside of 472.52%. Larimar Therapeutics has a consensus target price of $12.71, indicating a potential upside of 241.78%. Given Cardiff Oncology's higher possible upside, equities analysts plainly believe Cardiff Oncology is more favorable than Larimar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

Cardiff Oncology has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 8.5% of Cardiff Oncology shares are held by insiders. Comparatively, 4.5% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Larimar Therapeutics had 6 more articles in the media than Cardiff Oncology. MarketBeat recorded 8 mentions for Larimar Therapeutics and 2 mentions for Cardiff Oncology. Larimar Therapeutics' average media sentiment score of 1.07 beat Cardiff Oncology's score of 0.94 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Larimar Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Cardiff Oncology's return on equity of -95.51% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
Larimar Therapeutics	N/A	-134.14%	-96.00%

Cardiff Oncology has higher revenue and earnings than Larimar Therapeutics. Cardiff Oncology is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	151.80	-$45.85M	-$0.67	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A

Summary

Cardiff Oncology and Larimar Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to Immuneering?

Cardiff Oncology (NASDAQ:CRDF) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

In the previous week, Immuneering had 4 more articles in the media than Cardiff Oncology. MarketBeat recorded 6 mentions for Immuneering and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.94 beat Immuneering's score of 0.93 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuneering	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 8.5% of Cardiff Oncology shares are owned by insiders. Comparatively, 22.9% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cardiff Oncology presently has a consensus target price of $7.50, suggesting a potential upside of 472.52%. Immuneering has a consensus target price of $16.57, suggesting a potential upside of 218.07%. Given Cardiff Oncology's higher probable upside, equities analysts plainly believe Cardiff Oncology is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Immuneering has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Immuneering's return on equity of -31.93% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
Immuneering	N/A	-31.93%	-29.92%

Cardiff Oncology has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

Cardiff Oncology has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	151.80	-$45.85M	-$0.67	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

Summary

Immuneering beats Cardiff Oncology on 9 of the 16 factors compared between the two stocks.

Get Cardiff Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDF vs. The Competition

Export

Metric	Cardiff Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$92.30M	$3.68B	$6.85B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-1.96	20.98	27.01	24.38
Price / Sales	151.80	311.11	522.34	92.57
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	1.96	8.54	10.80	6.33
Net Income	-$45.85M	$23.83M	$3.59B	$331.02M
7 Day Performance	4.80%	-2.77%	-1.49%	-0.33%
1 Month Performance	-7.75%	5.85%	2.79%	-1.29%
1 Year Performance	-68.20%	52.15%	28.56%	21.30%

Cardiff Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDF Cardiff Oncology	3.7495 of 5 stars	$1.31 -3.0%	$7.50 +472.5%	-68.3%	$92.30M	$590K	N/A	20
AMRN Amarin	1.803 of 5 stars	$15.73 -3.9%	N/A	-10.7%	$343.26M	$213.65M	N/A	360	Analyst Upgrade
INDP Indaptus Therapeutics	1.102 of 5 stars	$2.85 -5.9%	N/A	-79.1%	$343.12M	N/A	N/A	6	Positive News Short Interest Decrease
FATE Fate Therapeutics	3.6904 of 5 stars	$2.99 +2.4%	$5.13 +71.4%	+162.3%	$340.35M	$6.65M	N/A	550
LRMR Larimar Therapeutics	4.3578 of 5 stars	$3.29 +0.9%	$12.71 +286.5%	+7.8%	$338.66M	N/A	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDF) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiff Oncology (CRDF) Competitors

CRDF vs. AMRN, INDP, FATE, LRMR, and IMRX

How does Cardiff Oncology compare to Amarin?

Summary

How does Cardiff Oncology compare to Indaptus Therapeutics?

Summary

How does Cardiff Oncology compare to Fate Therapeutics?

Summary

How does Cardiff Oncology compare to Larimar Therapeutics?

Summary

How does Cardiff Oncology compare to Immuneering?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF vs. The Competition

Cardiff Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiff Oncology (CRDF) Competitors

CRDF vs. AMRN, INDP, FATE, LRMR, and IMRX

How does Cardiff Oncology compare to Amarin?

Which has stronger valuation & earnings, AMRN or CRDF?

Which has more risk & volatility, AMRN or CRDF?

Does the media prefer AMRN or CRDF?

Do institutionals & insiders believe in AMRN or CRDF?

Is AMRN or CRDF more profitable?

Do analysts rate AMRN or CRDF?

Summary

How does Cardiff Oncology compare to Indaptus Therapeutics?

Does the media refer more to CRDF or INDP?

Is CRDF or INDP more profitable?

Which has more risk and volatility, CRDF or INDP?

Which has preferable earnings and valuation, CRDF or INDP?

Do institutionals and insiders believe in CRDF or INDP?

Do analysts rate CRDF or INDP?

Summary

How does Cardiff Oncology compare to Fate Therapeutics?

Which has stronger valuation and earnings, FATE or CRDF?

Do analysts rate FATE or CRDF?

Which has more risk & volatility, FATE or CRDF?

Do institutionals & insiders believe in FATE or CRDF?

Does the media refer more to FATE or CRDF?

Is FATE or CRDF more profitable?

Summary

How does Cardiff Oncology compare to Larimar Therapeutics?

Do analysts prefer CRDF or LRMR?

Which has more risk & volatility, CRDF or LRMR?

Do insiders and institutionals hold more shares of CRDF or LRMR?

Does the media refer more to CRDF or LRMR?

Is CRDF or LRMR more profitable?

Which has higher valuation and earnings, CRDF or LRMR?

Summary

How does Cardiff Oncology compare to Immuneering?

Does the media favor CRDF or IMRX?

Do insiders and institutionals hold more shares of CRDF or IMRX?

Do analysts rate CRDF or IMRX?

Is CRDF or IMRX more profitable?

Which has more risk & volatility, CRDF or IMRX?

Which has higher earnings & valuation, CRDF or IMRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF vs. The Competition

Cardiff Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools